Voluntary nationwide recall: Clonazepam (Endo – July)

Sep. 2024Pharmacy Updates

Endo USA Inc. has recalled one lot of Clonazepam Orally Disintegrating Tablets, USP (C-IV) 0.25 mg. Clonazepam is used to treat panic disorder and certain seizures.

This product is being recalled because the cartons of some packs show the product strength as 0.125 mg, not 0.25 mg, due to an error at a third-party packager. The blister strips inside the product pack reflect the correct strength of 0.25 mg.

Using this drug at a higher dose than prescribed may cause sleepiness, dizziness, loss of muscle control, and confusion.

As of July 16, there had been no reports of adverse events related to this recall.

To learn more about this recall:

  • Call Inmar Inc. at 1-877-890-0765. Help is available Monday through Friday from 9 a.m. to 5 p.m. ET.
  • Visit the FDA website.

Recent Announcements

Clinical workflow changes through Epic®

Changes are coming for network providers that utilize Provider OnLine to submit specific information to UPMC Health Plan. Select activities that were previously completed in Provider OnLine will now transition to UPMC Health Plan Tapestry Link.
Oct. 2026Important Notices

Provider Directory Updates and Required Attestation

As you know, UPMC Health Plan requires all providers to verify their provider directory information at least every 90 days (quarterly).
Oct. 2026Important Notices

CME Webinar: Getting it Right from the Start: Identifying Patient Advanced Care Directives

Please join us for a live, CME-accredited webinar on Thursday, Oct. 15, 2026 that will educate providers on identifying advanced directives and surrogate decision makers on admission.
Oct. 2026Education/Webinars